Ets-1 regulates intracellular glutathione levels: Key target for resistant ovarian cancer

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Verschoor, Meghan L ^a   Singh, Gurmit ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Drug resistance; Ets 1; Glutathione; Ovarian cancer; Oxidative stress

Indexed keywords

CRYSTAL VIOLET; GLUCOSE OXIDASE; GLUTAMIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 2; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR ETS 1;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GLUCOSE OXIDATION; GLUTATHIONE INTRACELLULAR LEVEL; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; OVARY CANCER; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; WESTERN BLOTTING;

AMINO ACID TRANSPORT SYSTEM Y+; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OVARIAN NEOPLASMS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEIN C-ETS-1; SULFASALAZINE;

EID: 84887515532     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-138     Document Type: Article

References (45)

1. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 2013, 10:211-224. 10.1038/nrclinonc.2013.5, 23381004.
2. Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol 2013, 3:251. 3781360, 24069583.
3. Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, et al. Ovarian cancer stem cells. Neoplasma 2012, 59:747-755. 10.4149/neo_2012_094, 22862176.
4. Guddati AK. Ovarian cancer stem cells: elusive targets for chemotherapy. Med Oncol 2012, 29:3400-3408. 10.1007/s12032-012-0252-6, 22638913.
5. Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C. Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev 2012, 8:994-1010. 10.1007/s12015-011-9344-5, 22278130.
6. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010, 10:268-278. 10.2174/156800910791190175, 20370691.
7. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 2012, 1271:58-67. 10.1111/j.1749-6632.2012.06734.x, 3499654, 23050965.
8. Wilson LA, Yamamoto H, Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 2004, 3:823-832.
9. Verschoor ML, Verschoor CP, Singh G. Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers. Cancer & Metabolism 2013, 1:17.
10. Verschoor ML, Wilson LA, Verschoor CP, Singh G. Ets-1 regulates energy metabolism in cancer cells. PLoS One 2010, 5:e13565. 10.1371/journal.pone.0013565, 2962648, 21042593.
11. Burhans WC, Heintz NH. The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 2009, 47:1282-1293. 10.1016/j.freeradbiomed.2009.05.026, 19486941.
12. Singh S, Khan AR, Gupta AK. Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol 2012, 9:303-316.
13. Ryu CS, Kwak HC, Lee JY, Oh SJ, Phuong NT, Kang KW, Kim SK. Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol 2013, 85:197-206. 10.1016/j.bcp.2012.10.021, 23123664.
14. Syed Alwi SS, Cavell BE, Donlevy A, Packham G. Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones 2012, 17:529-538. 10.1007/s12192-012-0329-3, 3535168, 22351438.
15. Guha P, Dey A, Sen R, Chatterjee M, Chattopadhyay S, Bandyopadhyay SK. Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther 2011, 336:206-214. 10.1124/jpet.110.171983, 20876229.
16. Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM. Glutathione levels in human tumors. Biomarkers 2012, 17:671-691. 10.3109/1354750X.2012.715672, 22900535.
17. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997, 79:521-527. 10.1002/(SICI)1097-0142(19970201)79:3<521::AID-CNCR14>3.0.CO;2-5, 9028363.
18. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer. Curr Oncol 2010, 17:9-16.
19. Hahne JC, Okuducu AF, Sahin A, Fafeur V, Kiriakidis S, Wernert N. The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem 2008, 8:1095-1105. 10.2174/138955708785909934, 18855726.
20. Verschoor ML, Wilson LA, Singh G. Mechanisms associated with mitochondrial-generated reactive oxygen species in cancer. Can J Physiol Pharmacol 2010, 88:204-219. 10.1139/Y09-135, 20393586.
21. Alipov G, Nakayama T, Ito M, Kawai K, Naito S, Nakashima M, Niino D, Sekine I. Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology 2005, 46:202-208. 10.1111/j.1365-2559.2005.02059.x, 15693893.
22. Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O'Higgins N, Duffy MJ. Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 2004, 91:1308-1315. 10.1038/sj.bjc.6602128, 2409905, 15365563.
23. Chang XZ, Yu J, Zhang XH, Yin J, Wang T, Cao XC. Enhanced expression of trophinin promotes invasive and metastatic potential of human gallbladder cancer cells. J Cancer Res Clin Oncol 2009, 135:581-590. 10.1007/s00432-008-0492-1, 18846386.
24. Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001, 7:551-557.
25. Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope CG, Kristensen GB, Bryne M, Reich R. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 2001, 25:1493-1500. 10.1097/00000478-200112000-00004, 11717538.
26. Fujimoto J, Aoki I, Toyoki H, Khatun S, Sato E, Sakaguchi H, Tamaya T. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 2004, 66:420-428. 10.1159/000079491, 15331930.
27. Katayama S, Nakayama T, Ito M, Naito S, Sekine I. Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. Histol Histopathol 2005, 20:119-126.
28. Saeki H, Oda S, Kawaguchi H, Ohno S, Kuwano H, Maehara Y, Sugimachi K. Concurrent overexpression of Ets-1 and c-Met correlates with a phenotype of high cellular motility in human esophageal cancer. Int J Cancer 2002, 98:8-13. 10.1002/ijc.10163, 11857377.
29. Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 2001, 101:242-247. 10.1006/jsre.2001.6279, 11735282.
30. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 2002, 21:8506-8509. 10.1038/sj.onc.1206040, 12466970.
31. Wilson LA, Gemin A, Espiritu R. Singh G: ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB J 2005, 19:2085-2087.
32. Azad MB, Chen Y, Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 2009, 11:777-790. 10.1089/ars.2008.2270, 18828708.
33. Higuchi Y, Yoshimoto T. Arachidonic acid converts the glutathione depletion-induced apoptosis to necrosis by promoting lipid peroxidation and reducing caspase-3 activity in rat glioma cells. Arch Biochem Biophys 2002, 400:133-140. 10.1006/abbi.2002.2784, 11913980.
34. Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009, 34:176-188. 10.1016/j.tibs.2008.12.008, 19321346.
35. Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK, Chen GF. Regulation of hypoxia inducible factor-1alpha expression by the alteration of redox status in HepG2 cells. J Exp Clin Cancer Res 2011, 30:61. 10.1186/1756-9966-30-61, 3113749, 21595915.
36. Badawi Y, Ramamoorthy P, Shi H. Hypoxia-inducible factor 1 protects hypoxic astrocytes against glutamate toxicity. ASN Neuro 2012, 4:231-241. 10.1042/AN20120006, 3363983, 22540931.
37. Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR, Schafer H. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003, 104:469-476. 10.1002/ijc.10963, 12584745.
38. Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, Wang YZ. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol 2009, 64:463-472. 10.1007/s00280-008-0894-4, 19104813.
39. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 2007, 67:3878-3887. 10.1158/0008-5472.CAN-06-3191, 17440102.
40. Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge C, Liang L, Jia D, Chen T, Yao M, et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett 2011, 312:55-61. 10.1016/j.canlet.2011.07.024, 21906871.
41. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 2007, 67:162-171. 10.1002/pros.20508, 17075799.
42. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy 2007, 53:210-217. 10.1159/000100812, 17356269.
43. Andrews PA, Albright KD. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 1992, 52:1895-1901.
44. Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun 2010, 391:91-95. 10.1016/j.bbrc.2009.10.168, 19896463.
45. Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006, 1:3159-3165.